This clinical trial will assess the impact of a new diet on the health of people with type 1 diabetes (T1D). The trial will take place in Sydney, Australia. The main outcome to be measured in change in HbA1c (average blood glucose over 3 months).
The details
T1D is an autoimmune disorder. This means that the body’s own immune system destroys the pancreas. The pancreas produces insulin (hormone that regulates blood glucose). When the pancreas is destroyed in T1D, insulin is decreased, and blood glucose rises. Very high blood glucose can lead to complications. Treatment for T1D includes insulin replacement, and diet changes.
This study will examine the use of a new diet. This diet has been designed to reduce increases in blood glucose after a meal, reduce the immune cells responsible for destroying the cells that produce insulin, improve the activity and variety of bacteria in the gut, and reduce inflammation. The outcomes for this study include changes in average blood glucose and measures of inflammation in the body.
Who are they looking for?
This study is looking to recruit 20 adults with T1D diabetes. Participants may not be pregnant or breastfeeding during the study.
How will it work
The participants will be randomly assigned to begin either the standard diet recommended in Australia, or to begin the novel diet. This diet is a Mediterranean style diet, lower in carbohydrates, and high in fiber.
After 3 months the participant’s HbA1c (measures average blood glucose over the last 3 months) will be measured. At this time the levels of immune cells in the blood, the level of C-peptide (indicator of pancreatic function) in the urine, and the bacteria in the gut will also be measured.
